Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bluebird Bio
(NQ:
BLUE
)
0.9753
-0.0089 (-0.90%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Bluebird Bio
< Previous
1
2
3
4
5
6
7
8
9
Next >
bluebird bio, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04, 2021
From
bluebird bio, Inc.
Via
Business Wire
Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies
July 28, 2021
From
bluebird bio, Inc. and Resilience
Via
Business Wire
bluebird bio Receives EC Approval for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age With Early Cerebral Adrenoleukodystrophy (CALD) Without Matched Sibling Donor
July 21, 2021
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Announces Positive Recommendation by PRAC Regarding Article 20 Safety Referral Review of ZYNTEGLO™ Gene Therapy for Transfusion-Dependent β-thalassemia and Marketing to Resume in EU
July 09, 2021
From
bluebird bio, Inc.
Via
Business Wire
BLUEBIRD BIO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of bluebird bio, Inc. - BLUE
June 11, 2021
From
Kahn Swick & Foti, LLC
Via
Business Wire
betibeglogene autotemcel (beti-cel) One-Time Gene Therapy for β-thalassemia Continues to Demonstrate Durable Efficacy Across Pediatric and Adult Patient Populations and All Genotypes in Data Presented at EHA2021 Virtual
June 11, 2021
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio to Present at Goldman Sachs Global Healthcare Conference
June 07, 2021
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia Studies
June 07, 2021
From
bluebird bio
Via
Business Wire
bluebird bio, Inc. Reports Inducement Grants to CCO Tom Klima Under Nasdaq Listing Rule 5635(c)(4)
June 02, 2021
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Receives Positive CHMP Opinion for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age with Early Cerebral Adrenoleukodystrophy (CALD)
May 21, 2021
From
bluebird bio, Inc.
Via
Business Wire
Long-Term Data from Pivotal KarMMa Study Continue to Demonstrate Deep and Durable Responses and Predictable Safety Profile with Bristol Myers Squibb and bluebird bio’s Abecma (idecabtagene vicleucel) in Relapsed or Refractory Multiple Myeloma
May 19, 2021
From
Bristol Myers Squibb
Via
Business Wire
bluebird bio to Present Data from Its Severe Genetic Disease and Oncology Portfolios During the EHA2021 Virtual Congress
May 13, 2021
From
bluebird bio, Inc.
Via
Business Wire
NASDAQ:BLUE Long Term Investor Alert: Investigation of Potential Wrongdoing at Bluebird Bio Inc
May 12, 2021
San Diego, CA -- (SBWIRE) -- 05/12/2021 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors of bluebird bio Inc.
Via
SBWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
bluebird bio Reports First Quarter Financial Results and Highlights Operational Progress
May 05, 2021
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Announces May Investor Events
May 03, 2021
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Provides Update on Severe Genetic Disease Programs and Business Operations
April 20, 2021
From
bluebird bio, Inc.
Via
Business Wire
DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
April 13, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
April 12, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
TUESDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
April 09, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird bio, Inc. (BLUE)
April 09, 2021
From
The Law Offices of Frank R. Cruz
Via
Business Wire
TUESDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
April 08, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
TUESDAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
April 07, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against bluebird bio, Inc. and Encourages Investors to Contact the Firm
April 06, 2021
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.